Compounds > resiquimod
Page last updated: 2024-09-04

resiquimod and lipoteichoic acid

resiquimod has been researched along with lipoteichoic acid in 3 studies

Compound Research Comparison

Studies
(resiquimod)		Trials
(resiquimod)		Recent Studies (post-2010)
(resiquimod)		Studies
(lipoteichoic acid)		Trials
(lipoteichoic acid)		Recent Studies (post-2010) (lipoteichoic acid)
465143181,62512646

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Czerniecki, BJ; Koldovsky, U; Koski, G; Roses, RE; Xu, M; Xu, S1
Caisová, V; Chmelař, J; Jochmanová, I; Kopecký, J; Krejčová, G; Kvardová, K; Masáková, K; Nedbalová, P; Paďouková, L; Uher, O; Ženka, J1
Caisova, V; Chlastakova, A; Chmelar, J; Frejlachova, A; Hansen, P; Kopecky, J; Kvardova, K; Lencova, R; Masakova, K; Pacak, K; Padoukova, L; Skalickova, M; Uher, O; Venhauerova, A; Zenka, J; Zhuang, Z1

Other Studies

3 other study(ies) available for resiquimod and lipoteichoic acid

ArticleYear
Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists.
    Journal of immunology (Baltimore, Md. : 1950), 2008, Oct-01, Volume: 181, Issue:7

    Topics: Cell Differentiation; Cell Movement; Cells, Cultured; Coculture Techniques; Dendritic Cells; Humans; Imidazoles; Interferon-gamma; Interleukin-12; Interleukin-17; Interleukin-23; Ligands; Lipopolysaccharides; Myeloid Cells; Teichoic Acids; Toll-Like Receptors

2008
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
    International immunopharmacology, 2018, Volume: 59

    Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Female; Imidazoles; Immunotherapy; Lipopolysaccharides; Lymphocytes, Tumor-Infiltrating; Mannans; Melanoma, Experimental; Mice, Inbred C57BL; Neutrophils; Pancreatic Neoplasms; Phagocytosis; Poly I-C; Teichoic Acids; Toll-Like Receptors; Tumor Burden

2018
Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
    Cancer immunology, immunotherapy : CII, 2021, Volume: 70, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; CD40 Antigens; Imidazoles; Immunotherapy; Ligands; Lipopolysaccharides; Mannans; Mice; Pancreatic Neoplasms; Poly I-C; T-Lymphocytes; Teichoic Acids; Toll-Like Receptors

2021